PT-141 — known by its generic name bremelanotide and marketed in the United States as Vyleesi — is one of the few melanocortin-pathway peptides with an FDA-approved analog, approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors such as sildenafil and tadalafil, which act on peripheral vascular smooth muscle, PT-141 works centrally — activating the melanocortin-4 receptor (MC4R) in the hypothalamus to influence the brain circuitry underlying sexual motivation itself. This article covers the mechanism, clinical evidence, dosing protocols, side effects, and how PT-141 compares to PDE5 inhibitors and Melanotan II.
Vyleesi (bremelanotide) achieved FDA approval in 2019 based on statistically significant FSFI-D improvements across two Phase 3 RCTs enrolling more than 1,200 women (Kingsberg et al., Obstet Gynecol 2019).
Mechanism — The Melanocortin-4 Receptor Pathway
PT-141 is a synthetic cyclic analog of α-MSH, the ligand family governing pigmentation, appetite, and sexual behaviour via the central melanocortin system. It acts predominantly at the melanocortin-4 receptor (MC4R), with lower-affinity activity at MC3R and MC1R (Molinoff et al., 2003), densely expressed in the paraventricular nucleus (PVN) of the hypothalamus.
The downstream pathway of interest runs roughly as follows:
- MC4R activation in the PVN projects to the medial preoptic area (mPOA), long implicated in sexual motivation in animal models.
- Increased dopaminergic signalling in the mPOA — associated with heightened sexual interest and copulatory readiness.
- Oxytocin release from magnocellular PVN neurons, contributing to arousal-related effects.
- Autonomic outflow that can secondarily promote pelvic vasodilation — a downstream consequence of central arousal, not the primary mechanism (unlike PDE5 inhibitors).
This CNS-first architecture is the key distinction in PT-141 research: it targets desire and central arousal, while PDE5 inhibitors target the mechanical erectile response once arousal is present.
PT-141 at a Glance
Tier A — Phase 3 RCT Evidence (HSDD Indication)| Parameter | Detail |
|---|---|
| Structure | Cyclic heptapeptide, deaminated derivative/metabolite of Melanotan II |
| Primary target | Melanocortin-4 receptor (MC4R); secondary MC3R/MC1R activity |
| Half-life | Approximately 2 hours (t½ 1.85–2.09 h; Diamond et al., 2004) |
| Route | Subcutaneous injection (most research protocols); intranasal spray achieves ~20-25% bioavailability |
| Typical research dose | 1–2 mg SubQ, 30–60 minutes before intended window of effect |
| Evidence tier | Tier A for the FDA-approved HSDD indication in women (Phase 3 RCT); investigational for male sexual dysfunction research |
| Bioactive Compounds reference price | £39 (10 mg vial, 99.29% purity) |
Clinical Evidence
PT-141's evidence base is unusually deep for a research peptide. Pivotal evidence underpinning FDA approval comes from the RECONNECT programme — two identical Phase 3 RCTs (Study 301 and 302) enrolling 1,247 premenopausal women with HSDD (Kingsberg et al., Obstet Gynecol 2019). Participants self-administered 1.75 mg bremelanotide or placebo subcutaneously, as needed, over 24 weeks. Co-primary endpoints were change in FSFI Desire domain (FSFI-D) and FSDS-DAO item 13. Both studies met endpoints with significant improvements in desire (+0.35, p<0.001) and reduced distress (−0.33, p<0.001) versus placebo.
RECONNECT built on an earlier Phase 2b dose-finding trial (Clayton et al., 2016), which identified 1.75 mg as the optimal efficacy/tolerability balance. On the male side, PT-141's history is longer but has not resulted in approval. Rosen et al. (2004) and Molinoff et al. (2003) established proof-of-concept in men, with significant erectile responses at intranasal doses above 7 mg. Diamond et al. (2006) extended this into women with arousal disorder, showing improved subjective arousal versus placebo.
Honesty matters here: later-stage male trials exploring higher subcutaneous doses (above 5 mg) were suspended amid blood pressure concerns, and approval for male sexual dysfunction was never completed. Research at the lower 1–2 mg range — now standard — has since shown a considerably more favourable cardiovascular profile.
| Trial | Population | Dose | Outcome | Result |
|---|---|---|---|---|
| RECONNECT (Studies 301 & 302) — Kingsberg et al., 2019 | 1,247 premenopausal women with HSDD | 1.75 mg SubQ, as needed, 24 weeks | FSFI-D, FSDS-DAO item 13 | Statistically significant improvement in desire (+0.35, p<0.001) and reduced distress (−0.33, p<0.001) vs placebo — basis for FDA approval |
| Phase 2b dose-finding — Clayton et al., 2016 | Premenopausal women with HSDD/FSAD | 0.75–1.75 mg SubQ | Satisfying sexual events, FSFI, FSDS-DAO | 1.25/1.75 mg pooled significantly improved SSEs (p=0.018) and FSFI total score (p=0.0017); dose selected for Phase 3 |
| Male ED pharmacokinetics — Rosen/Diamond et al., 2004 | Healthy men + Viagra-responsive ED patients | Intranasal 7–20 mg | RigiScan erectile response | Statistically significant erectile response above 7 mg; onset ~30 min; flushing/nausea most common AEs |
| Female arousal disorder — Diamond et al., 2006 | 18 premenopausal women with FSAD | Intranasal, in-clinic dosing | Subjective arousal/desire, vaginal photoplethysmography | Higher rates of moderate-to-high desire vs placebo (p=0.011); no adverse effects reported |
Dosing & Timing Protocols
Research protocols typically use 1–2 mg administered subcutaneously, taken 30–60 minutes prior to the intended window of effect. Onset occurs at approximately 30–45 minutes, with a window of receptor-mediated sensitivity lasting 6–8 hours. The RECONNECT protocol capped frequency at a maximum of 8 doses per month — a limit carried into the Vyleesi prescribing label. This ceiling is not arbitrary: higher or more frequent dosing is associated with tachyphylaxis, receptor desensitization in which repeated agonist exposure blunts the response. The operative principle is "less is more" — infrequent, as-needed dosing preserves receptor sensitivity better than daily administration.
Side Effect Profile From Trials
The FDA label and RECONNECT data give an honest picture of tolerability. Nausea is the dominant adverse event, reported by approximately 40% of participants — usually mild and improving with subsequent doses, though it required anti-emetic therapy in 13% and discontinuation in 8% (FDA Vyleesi label, 2019). Flushing, headache, and injection site reactions round out the most common events. A small, transient rise in blood pressure — roughly 2–6 mmHg systolic in the first four hours post-dose — underlies the cardiovascular screening language in the label; ambulatory monitoring confirmed shifts were confined to that early window (Clayton et al., 2016). Focal skin hyperpigmentation — face, gingiva, or breasts — has been reported in about 1% of patients on repeated dosing, attributable to partial MC1R affinity. Unlike PDE5 inhibitors, PT-141 has not been associated with priapism in the female programme.
PT-141 vs PDE5 Inhibitors
Key mechanistic and practical differences:
| Property | PT-141 (Bremelanotide) | Sildenafil / Tadalafil (PDE5i) |
|---|---|---|
| Mechanism site | Central — MC4R in hypothalamus (PVN) | Peripheral — vascular smooth muscle (corpus cavernosum) |
| Onset | ~30–45 minutes | 30–60 min (sildenafil); up to several hours for tadalafil at low doses |
| Duration | ~6–8 hours of receptor-mediated sensitivity | 4–6 hours (sildenafil); up to 36 hours (tadalafil) |
| Effect on desire vs erection | Primarily desire/central arousal; downstream vasodilation is secondary | Erectile mechanism only — no direct effect on subjective desire |
| Alcohol interaction | No significant interaction reported in Phase 1 co-administration study | Alcohol can potentiate hypotensive effects |
| CV profile | Small transient BP increase post-dose; CV screening recommended | Contraindicated with nitrates; vasodilatory hypotension risk |
| Prescribing pathway | FDA-approved (Vyleesi) for female HSDD only | FDA-approved for male ED |
These are fundamentally different research tools. PT-141 asks whether centrally mediated desire and arousal can be pharmacologically influenced; PDE5 inhibitors ask whether the peripheral erectile mechanism can be facilitated once arousal is present. They represent non-overlapping research angles on sexual response.
PT-141 vs Melanotan II
PT-141 and Melanotan II share a common ancestry — PT-141 is a deaminated derivative and metabolite of Melanotan II — but their receptor selectivity diverges in ways that matter for research design. Melanotan II is broad-spectrum, active across MC1R, MC3R, MC4R, and MC5R, with dominant MC1R activity driving pronounced tanning/pigmentation effects alongside libido effects via MC3R/MC4R. PT-141 is comparatively MC4R-selective, engineered to preserve libido-related signalling while substantially reducing pigmentation response. In practice, Melanotan II protocols are framed around pigmentation research with a secondary libido observation, while PT-141 protocols are framed around sexual response research with minimal tanning as a side observation. See our forthcoming Melanotan II research profile for more detail.
Reconstitution, Storage & Administration
PT-141 is supplied as a lyophilized peptide and must be reconstituted with bacteriostatic (BAC) water prior to use. A common reference preparation uses a 10 mg vial with 2 mL BAC water, yielding a 5 mg/mL concentration — convenient for measuring 1–2 mg doses with a standard insulin syringe. Subcutaneous administration is preferred, offering more predictable pharmacokinetics than intranasal (only 20–25% bioavailability). Refrigerated (2–8°C), reconstituted solution is stable for approximately 4–6 weeks.
Bloodwork Before & During Research
Given the transient blood pressure effects documented in the literature, baseline cardiovascular characterisation is a sensible starting point. A reasonable panel: blood pressure (24-hour ambulatory monitoring is ideal), CBC, comprehensive metabolic panel, and testosterone (total and free) with SHBG for baseline hormonal context. Repeat blood pressure monitoring during and after a protocol provides the most direct safety signal. See our peptide bloodwork guide for the full panel and reference ranges.
Bloodwork Tracker
Track blood pressure, CBC, metabolic panel, and hormonal markers relevant to sexual-response peptide research.
Availability at Bioactive Compounds
Bioactive Compounds supplies PT-141 as a 10 mg vial at 99.29% purity for £39, intended strictly as an in-vitro research reference material for qualified researchers. PT-141 is not licensed for human therapeutic use, and nothing here should be interpreted as medical advice. All orders and research enquiries are handled directly via WhatsApp.
Continue Your Research
Frequently Asked Questions
PT-141 (bremelanotide) is a cyclic heptapeptide analog of α-MSH that activates the melanocortin-4 receptor (MC4R), primarily in the paraventricular nucleus of the hypothalamus. Unlike PDE5 inhibitors, which act on peripheral vascular smooth muscle, PT-141 works centrally in the CNS to increase dopaminergic signalling in the medial preoptic area, a region directly implicated in sexual motivation and arousal.
A bremelanotide formulation is FDA-approved as Vyleesi (1.75 mg subcutaneous auto-injector) for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT Phase 3 trial programme (Kingsberg et al., Obstet Gynecol 2019). It is not FDA-approved for male sexual dysfunction; that research remains investigational.
Research protocols commonly reference 1–2 mg administered subcutaneously, 30–60 minutes before the intended window of effect. The RECONNECT trials used 1.75 mg as needed, with a maximum frequency of 8 doses per month to avoid receptor desensitization (tachyphylaxis).
The most common adverse event across trials is nausea (approximately 40% in RECONNECT), which is usually mild and tends to subside with subsequent doses. Flushing, headache, and injection site reactions are also common. A small transient increase in blood pressure (roughly 2–6 mmHg systolic in the first few hours post-dose) is documented, and focal skin hyperpigmentation has been reported in about 1% of chronic users.
PDE5 inhibitors like sildenafil and tadalafil act peripherally on vascular smooth muscle to facilitate blood flow into erectile tissue but do not influence subjective desire. PT-141 acts centrally on MC4R in the hypothalamus, influencing dopaminergic arousal pathways that are more closely tied to sexual desire and motivation. They are mechanistically distinct research tools addressing different aspects of sexual response.
Both are melanocortin receptor agonists, but Melanotan II is broad-spectrum, with dominant activity at MC1R (driving pigmentation/tanning effects) alongside MC3R/MC4R activity. PT-141 is a more MC4R-selective metabolite of Melanotan II, engineered to preserve libido-related effects while substantially reducing the tanning response.
PT-141 is supplied as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic (BAC) water. A common reference preparation is a 10 mg vial reconstituted with 2 mL BAC water, yielding a 5 mg/mL concentration. Refrigerated, reconstituted solution is generally considered stable for approximately 4–6 weeks.
References
This article cites peer-reviewed research and the FDA prescribing label for bremelanotide (Vyleesi). Vyleesi is FDA-approved solely for HSDD in premenopausal women; PT-141 as supplied for research purposes is not licensed for human therapeutic use in the UK and is not approved by the MHRA.
- Kingsberg SA, Clayton AH, Portman D, et al (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 134(5), 899-908.
- Clayton AH, Althof SE, Kingsberg S, et al (2016). Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women's Health.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59.
- Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R (2006). An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist. Journal of Sexual Medicine, 3(4), 628-638.
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY (2003). PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction. Annals of the New York Academy of Sciences, 994(1), 96-102.
- Simon JA, Kingsberg SA, Portman D, et al (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology, 134(5), 909-917.
- U.S. Food and Drug Administration (2019). VYLEESI (bremelanotide injection) Prescribing Information.